Our findings for inverse correlation between AQP5 expression and ER/PR status, with the presence of gene amplifications of AQP5, may suggest a possible role of AQP5 targeted therapeutics for BC patients with hormone treatment resistances. Here, ESR1 is linked to breast cancer.